Han Kun represented Dongying Pharmaceuticals Co., Limited in the transfer of its domestic equity interest to Shanghai Pharma (SSE: 601607; HKEx: 02607)
2013-07-01
Dongying Pharmaceuticals Co., Limited completed the transfer of its equity interest in Dongying (Jiangsu) Pharmaceuticals Co., Ltd ("Dongying") to Shanghai Pharma (SSE: 601607; HKEx: 02607).
Han Kun represented Dongying Pharmaceuticals Co., Limited in this transaction.
Dongying engages in the business of production of high-end genetic pharmaceuticals.
Han Kun primarily assisted in the design of transaction structure, the due diligence investigation, the drafting and revision of relevant transaction documents, negotiation and deal closing.
The leading lawyers involved in this deal are Stanley Guo, Jason Wang, Adrian Lv, Yuan Lin, Nikki Yang and Alan Luo.